Leishmaniasis in Dogs
Explore the science behind leishmaniasis in dogs — how Leishmania parasites spread, symptoms to watch for, diagnosis, treatment options.
What Is Leishmaniasis in Dogs?
Leishmaniasis in dogs is a parasitic disease caused by Leishmania infantum (and less commonly L. donovani or L. tropica), transmitted primarily through the bite of infected female sand flies (Phlebotomus and Lutzomyia species). The parasite targets the dog's immune system — specifically macrophages, the very cells designed to destroy invaders — and can cause a spectrum of illness from silent, asymptomatic infection to severe multi-organ failure. It is a zoonotic disease, meaning it can also infect humans, though dogs are considered the primary reservoir host in endemic regions. If you suspect your dog has been exposed, consult your veterinarian immediately for diagnostic testing and a tailored treatment plan.
For dog owners in the southern United States, the Mediterranean basin, South America, or parts of Asia, leishmaniasis represents one of the most clinically complex vector-borne diseases in veterinary medicine. Even if you live outside endemic zones, imported rescue dogs and climate-driven sand fly range expansion make this a disease every informed owner should understand.
The Science Behind Leishmania: How the Parasite Hijacks the Immune System
The Macrophage Paradox
The Leishmania parasite's survival strategy is one of the most remarkable examples of immune evasion in parasitology. When an infected sand fly bites a dog, it injects promastigotes — the flagellated, motile form of the parasite — into the skin. Within hours, these promastigotes are engulfed by macrophages through phagocytosis, the standard immune process for destroying foreign invaders.
But instead of being destroyed inside the phagolysosome (the acidic compartment where pathogens are normally killed), Leishmania promastigotes transform into amastigotes — a smaller, non-motile form that not only survives but multiplies inside the macrophage. The parasite achieves this by:
- Inhibiting phagolysosomal acidification — raising the pH so digestive enzymes cannot function
- Producing surface molecules like lipophosphoglycan (LPG) and gp63 metalloprotease that neutralize oxidative burst mechanisms
- Modulating cytokine signaling — suppressing the Th1 (cell-mediated) immune response that would normally activate macrophage killing, while promoting a Th2 (humoral) response that produces antibodies but fails to clear intracellular parasites
This Th1/Th2 imbalance is the central mechanism determining disease outcome. Dogs that mount a strong cell-mediated (Th1) immune response tend to remain asymptomatic carriers. Dogs that produce a predominantly humoral (Th2) response — generating high levels of antibodies without effective cellular killing — develop clinical visceral leishmaniasis. Research published in the journal Parasites & Vectors has demonstrated that this immunological polarization correlates directly with disease severity and parasite load.
Once amastigotes rupture their host macrophage, they are released into surrounding tissue where they infect new macrophages, creating a cycle of progressive immune infiltration. The parasites disseminate through the reticuloendothelial system, accumulating in the lymph nodes, spleen, liver, bone marrow, and skin. This systemic spread is what produces the diverse clinical signs of canine leishmaniasis.
Evolutionary Context: Why Dogs Are the Primary Reservoir Host
The Ancient Dog-Parasite-Sand Fly Triangle
Leishmania infantum co-evolved with canids over thousands of years in the Mediterranean basin and Middle East. The domestic dog (Canis lupus familiaris) serves as the primary reservoir host — the species in which the parasite persists in nature and from which sand flies acquire infection to transmit to other hosts, including humans.
This reservoir relationship likely developed because ancestral dogs and wolves occupied ecological niches that overlapped heavily with sand fly habitats: ground-level sleeping, outdoor living in warm climates, and relatively thin skin on the muzzle, ears, and periocular regions where sand flies preferentially feed. Unlike cats, which are relatively resistant to Leishmania infection, canids lack certain innate immune mechanisms that would clear the parasite before it establishes systemic infection.
The evolutionary trade-off is significant: the parasite benefits from a long-lived, mobile host that maintains a chronic (rather than rapidly fatal) infection, ensuring ongoing transmission. The dog, meanwhile, suffers a disease that may not manifest clinically for months to years — meaning infected animals can spread the parasite extensively before any owner recognizes illness.
Clinical Signs: What Leishmaniasis Looks Like in Dogs
The clinical presentation of canine leishmaniasis is notoriously variable. According to the Merck Veterinary Manual, only about 10-20% of infected dogs develop overt clinical disease, while the remainder stay subclinical carriers — a fact that complicates both diagnosis and public health management.
| Body System | Common Signs | Frequency in Clinical Cases |
|---|---|---|
| Dermatological | Exfoliative dermatitis (silvery scaling), alopecia (especially periocular — "spectacle" pattern), ulcerative lesions on ear pinnae and muzzle, onychogryphosis (abnormally long, curved claws) | ~80% of symptomatic dogs |
| Lymphoreticular | Generalized lymphadenopathy (enlarged lymph nodes), splenomegaly (enlarged spleen), hepatomegaly (enlarged liver) | ~60-70% |
| Renal | Polyuria/polydipsia (excessive urination/thirst), proteinuria, progressive kidney failure (glomerulonephritis from immune complex deposition) | ~25-30% — primary cause of death |
| Ocular | Blepharitis, conjunctivitis, uveitis, keratoconjunctivitis sicca (dry eye) | ~20-25% |
| Constitutional | Weight loss (often with normal appetite), lethargy, muscle atrophy, fever, epistaxis (nosebleeds) | ~50-60% |
| Musculoskeletal | Lameness, polyarthritis, myositis | ~15-20% |
The incubation period is highly variable — typically 2 to 8 months after the infective sand fly bite, though cases have been documented with incubation periods exceeding 7 years in subclinically infected dogs whose immune status later changed (for example, following immunosuppressive therapy or concurrent illness).
Diagnosis and Treatment: What to Expect at the Vet
Diagnostic Testing
Veterinarians use a combination of serological, molecular, and cytological tests to diagnose leishmaniasis. Expect your vet to recommend one or more of the following:
- Quantitative serology (IFAT or ELISA): Detects anti-Leishmania antibodies. Titers above 1:80 on IFAT are generally considered clinically significant, though cutoff values vary by laboratory and endemic status. Cost range: $80-$150.
- PCR (polymerase chain reaction): Detects Leishmania DNA in blood, bone marrow, or lymph node aspirates. Highly sensitive and specific. Cost range: $120-$250.
- Cytology of bone marrow or lymph node aspirates: Direct visualization of amastigotes inside macrophages. Definitive but sensitivity depends on sample quality. Cost range: $150-$300 including procedure.
- Complete blood count and biochemistry panel: Typically reveals hyperglobulinemia (elevated globulins), hypoalbuminemia, non-regenerative anemia, thrombocytopenia, and elevated BUN/creatinine if renal involvement exists. Cost range: $150-$250.
- Urinalysis with urine protein:creatinine ratio (UPC): Critical for assessing renal damage, which is the most common cause of death. Cost range: $40-$80.
Treatment Protocols
Treatment for canine leishmaniasis is prolonged, expensive, and — critically — does not achieve parasitological cure. The goal is clinical remission: reducing parasite load to the point where symptoms resolve and quality of life improves. According to the LeishVet guidelines, the standard protocol includes:
| Medication | Dosage | Duration | Estimated Cost | Notes |
|---|---|---|---|---|
| Meglumine antimoniate (Glucantime®) | 100 mg/kg SC once daily or 50 mg/kg SC twice daily | 4-8 weeks (initial course) | $400-$900 per course | First-line leishmanicidal drug; not FDA-approved in the US; imported under veterinary special permit |
| Miltefosine (Milteforan®) | 2 mg/kg PO once daily with food | 4 weeks | $300-$600 per course | Alternative to antimonials; oral administration; GI side effects common |
| Allopurinol | 10 mg/kg PO twice daily | Minimum 6-12 months, often lifelong | $15-$40/month | Leishmaniostatic (prevents replication); used in combination with above or as long-term maintenance |
| Domperidone (Leisguard®) | 0.5 mg/kg PO once daily | 1 month courses, repeated | $30-$60/month | Immunomodulator; enhances Th1 response; used as adjunctive therapy or prophylaxis in endemic areas |
Relapse is common — approximately 30-50% of clinically treated dogs experience recurrence of symptoms within 6-24 months, requiring additional treatment courses. Dogs with advanced renal disease (IRIS stage III or IV) have a guarded to poor prognosis, as kidney damage from immune complex glomerulonephritis is irreversible.
Geographic Distribution and the Changing Risk Map
Historically, canine leishmaniasis was considered a disease of the Mediterranean, Middle East, South America (especially Brazil), and parts of Asia. In the United States, Leishmania infantum was first documented in foxhounds in 2000, with vertical (mother-to-puppy) transmission identified as a key maintenance mechanism in the absence of competent sand fly vectors.
As of 2026, the risk landscape has shifted:
- Sand fly vectors (Lutzomyia longipalpis and related species) have been documented expanding northward in the Americas, with established populations now confirmed in parts of Texas, Oklahoma, and occasionally as far north as Ohio during warm seasons.
- International dog rescue has introduced Leishmania-positive dogs into non-endemic regions. Dogs rescued from Mediterranean countries, North Africa, and South America may carry subclinical infections that manifest months after adoption.
- Vertical transmission (transplacental) and venereal transmission have been documented, meaning the disease can spread within kennels and breeding populations without any sand fly involvement.
- Rare blood transfusion transmission has been reported, underscoring the importance of screening blood donors in endemic areas.
Prevention Strategies: Protecting Your Dog
What Owners Can Do
- Sand fly repellent collars and spot-ons: Deltamethrin-impregnated collars (e.g., Scalibor®) and permethrin spot-on products have demonstrated 86-95% efficacy in reducing sand fly bites in field studies. Apply from early spring through late autumn in endemic regions. Cost: $25-$60 per collar lasting 5-6 months.
- Environmental management: Sand flies are most active at dawn and dusk. Keep dogs indoors during these peak feeding times. Remove organic debris and standing water near sleeping areas. Fine-mesh screens (aperture <0.4 mm) on kennels and windows reduce indoor exposure.
- Vaccination: Two vaccines are available in Europe (CaniLeish® and Letifend®), with reported efficacy of approximately 68-72% in preventing clinical disease. Neither vaccine is currently USDA-approved for use in the United States. Vaccination does not prevent infection — it reduces the probability of progressing from subclinical infection to clinical disease.
- Pre-breeding and pre-adoption screening: If adopting a dog from an endemic region (Mediterranean, South America, Middle East), request quantitative IFAT or ELISA serology before or immediately upon arrival. A negative titer does not guarantee the dog is uninfected — early-stage infections may be seronegative — so retesting at 6 months is recommended.
- Avoid breeding infected dogs: Because vertical transmission is documented, Leishmania-positive bitches should not be bred. Responsible breeders in endemic areas screen all breeding stock annually.
Common Misconceptions Debunked
| Myth | Fact |
|---|---|
| "My dog doesn't leave the yard, so they can't get leishmaniasis." | Sand flies travel up to 2 km from breeding sites and readily enter homes. A single bite from an infected fly is sufficient for transmission. |
| "Leishmaniasis is always fatal." | With early diagnosis and appropriate treatment, many dogs achieve long-term clinical remission and live for years with managed disease. However, untreated clinical leishmaniasis is progressive and ultimately fatal in most cases. |
| "If my dog tests positive, they need to be euthanized." | A positive antibody titer in an asymptomatic dog does not necessarily mean clinical disease will develop. Many seropositive dogs remain subclinical lifelong. Treatment decisions should be based on clinical signs, parasite load, and organ function — not serology alone. |
| "Humans catch leishmaniasis directly from their dogs." | Direct dog-to-human transmission has not been documented under normal circumstances. Both dogs and humans are infected independently through sand fly bites. However, dogs serve as the reservoir, so an infected dog in your home indicates environmental risk. |
| "Leishmaniasis only affects dogs in tropical countries." | Autochthonous (locally acquired) cases have been documented in the United States, particularly among foxhound kennels and in southern states where sand fly vectors exist. |
Breed Predispositions and Variations
While any dog can be infected, research has identified breed-related differences in susceptibility and disease expression:
- Boxers, Cocker Spaniels, Rottweilers, and German Shepherds appear overrepresented in clinical case series, suggesting genetic susceptibility factors. Studies have linked specific MHC class II alleles (DLA-DRB1) to increased risk of symptomatic disease.
- Ibizan Hounds show a notably high rate of asymptomatic infection despite exposure, suggesting a genetic resistance mechanism linked to a robust Th1 cellular response.
- Foxhounds in the US represent a unique epidemiological cluster where vertical transmission maintains the parasite within breeding lines independent of sand fly vectors.
- Age is a significant factor: clinical disease shows a bimodal age distribution, with peaks in dogs under 3 years and over 8 years — correlating with periods of relative immune immaturity and immunosenescence, respectively.
When Leishmaniasis Mimics Other Diseases
One of the greatest diagnostic challenges of canine leishmaniasis is its ability to mimic numerous other conditions. The combination of skin lesions, kidney disease, and lymphadenopathy can resemble:
- Ehrlichiosis and Anaplasmosis (other tick/vector-borne diseases with overlapping hematological findings)
- Systemic lupus erythematosus (autoimmune disease with similar immune complex-mediated kidney damage)
- Lymphoma (particularly when lymphadenopathy and weight loss are the primary signs)
- Demodicosis (skin lesions and alopecia that can appear similar)
- Chronic kidney disease from other causes (when renal signs predominate)
This diagnostic overlap means that any dog in or from an endemic area presenting with chronic, multi-systemic illness should have leishmaniasis on the differential list. Your veterinarian may recommend a vector-borne disease panel that tests for multiple tick- and sand fly-borne pathogens simultaneously, typically costing $200-$400.
Frequently Asked Questions
Can leishmaniasis in dogs be cured completely?
No current treatment achieves complete parasitological cure. The parasite persists in tissues at low levels even after successful clinical treatment. However, many dogs achieve stable clinical remission with combination therapy and long-term allopurinol maintenance, living good-quality lives for years. Relapse monitoring through regular veterinary checkups (every 3-6 months) with repeat bloodwork and serology is essential.
Is leishmaniasis contagious between dogs?
Direct dog-to-dog transmission through casual contact (sharing water bowls, playing, sleeping together) does not occur. The primary route is sand fly vector transmission. However, vertical (mother-to-puppy), venereal, and blood transfusion transmission have been documented. In non-endemic areas where sand flies are absent, these non-vector routes become epidemiologically significant.
How does canine leishmaniasis differ from human leishmaniasis?
Dogs and humans are infected by the same parasite through the same vector, but dogs are the primary reservoir host while humans are considered incidental hosts. In humans, L. infantum causes visceral leishmaniasis (kala-azar), which is fatal without treatment. Cutaneous forms (caused by different Leishmania species) are more common in humans than dogs. Treatment protocols differ significantly between species — drugs used in dogs are not identical to those in human medicine.
What does it mean when my dog has a high Leishmania antibody titer but no symptoms?
A high titer (e.g., IFAT ≥1:160) in an asymptomatic dog indicates significant immune exposure to Leishmania. According to LeishVet staging, this dog would be classified as "Stage I — subclinical infection" and may never develop clinical disease. Recommendations typically include monitoring every 6 months with repeat serology, CBC, biochemistry, and urinalysis. Some veterinarians in highly endemic areas recommend prophylactic allopurinol or domperidone, though this remains debated.
Should I avoid adopting a dog from a Mediterranean rescue?
Not necessarily — but you should go in with eyes open. Request pre-adoption screening (quantitative serology and PCR if possible). Budget for potential veterinary costs: even a subclinically infected dog may require lifelong monitoring ($200-$400/year in bloodwork) and could develop clinical disease requiring treatment ($1,000-$3,000+). Many rescued Mediterranean dogs live long, healthy lives — but informed preparation prevents heartbreaking financial and emotional surprises.
Is there a leishmaniasis vaccine available for dogs in the US?
As of 2026, no Leishmania vaccine is USDA-approved for use in the United States. European vaccines (CaniLeish®, Letifend®) are available in endemic countries but cannot be legally imported for general veterinary use in the US. Prevention in the US relies on vector avoidance through repellent products, environmental management, and screening.
References and Further Reading
- Baneth, G. et al. "Canine leishmaniosis — new concepts and insights on an expanding zoonosis: part one." Trends in Parasitology, 24(7), 2008. Available via PubMed Central.
- LeishVet Guidelines on Canine Leishmaniosis. leishvet.org.
- Merck Veterinary Manual: Leishmaniasis in Dogs. merckvetmanual.com.
This article is for educational purposes and does not replace professional veterinary advice. If your dog shows signs consistent with leishmaniasis — particularly chronic skin changes, unexplained weight loss, enlarged lymph nodes, or increased thirst/urination — schedule a veterinary appointment promptly. Early diagnosis significantly improves treatment outcomes and quality of life.
Jonas Cole
All our authors care for dogs every day — read more of their work on the authors page.
